Biotech Values

[DewDiligence]

>> My first thought from the PR yesterday, was a comment Dr. Levitt made regarding Roche awhile back or was it Takeda were looking for IL-9 components and they were waiting on the IP position to strengthen before they licensed. <<

katie: My recollection is that Dr Levitt said Roche and Takeda were active in this research area --I do not recall any comment that these companies were interested in licensing IL-9-related IP from GENR.

You could be right about MEDI, but I maintain that yesterday’s GENR PR about the Ludwig alliance is odd. Here’s an excerpt from the 2001 PR announcing the GENR-MEDI collaboration for IL-9:

>>
MedImmune, Inc. and Genaera Corporation today announced that they have entered into a research collaboration and a worldwide exclusive licensing agreement to develop and commercialize antibodies or recombinant molecules against IL-9 to prevent symptoms of asthma and other respiratory diseases.
<<

Here’s an excerpt from yesterday’s GENR PR:

>>
Genaera Corporation and the Ludwig Institute for Cancer Research (LICR) today announced a two-year extension of a collaborative agreement on the joint discovery and development of novel genes and proteins as pharmaceutical targets and therapeutics, including further research related to interleukin-9 (IL-9).
<<

Does the “further research related to” IL-9 overlap in any way with the scope of the MEDI collaboration? I would have expected yesterday’s PR to attempt to clarify on this point.